Polomar Health Services, Inc. (PMHS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Polomar Health Services, Inc. (PMHS) trades at $0.151. Polomar Health Services, Inc. operates a retail compounding pharmacy specializing in customized medications, including weight management via its SlimRx online platform. Market cap: $4.24M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for PMHS: PMHS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PMHS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on PMHS.
How is this calculated? →Polomar Health Services, Inc. (PMHS) Healthcare & Pipeline Overview
Polomar Health Services, Inc. is a Los Angeles-based retail compounding pharmacy specializing in customized medications, including weight management via SlimRx, personalized dermatology, and upcoming diabetes and ED treatments through PoloMeds. The company also supports third-party telehealth platforms with prescription fulfillment services.
What Is the Investment Thesis for PMHS?
Polomar Health Services, Inc. presents an investment thesis centered on its specialization in compounding pharmacy services and strategic expansion into high-demand therapeutic areas. The company's ownership of SlimRx, an online weight management platform leveraging compounded semaglutide, taps into a growing market driven by increasing obesity rates. The planned launch of PoloMeds for diabetes and erectile dysfunction treatments further diversifies its offerings into significant chronic care markets. Supporting third-party telehealth platforms also positions PMHS to benefit from the ongoing shift towards digital healthcare delivery. Key value drivers include the increasing demand for personalized medicine, the convenience of online platforms, and the potential for higher margins on custom compounds, as evidenced by a gross margin of 61.1%. However, the company operates with a negative profit margin of -622.7% and a market capitalization of $4.24M, indicating significant unprofitability and a very small scale. Its OTC Other tier listing and a Beta of -1.14 suggest potential for high volatility and unique market dynamics, necessitating careful evaluation of operational stability and regulatory compliance within the compounding sector.
Based on FMP financials and quantitative analysis
PMHS Key Highlights
The company maintains a strong gross margin of 61.1%, indicating efficient cost management relative to its revenue from specialized compounded medications.
- Polomar Health Services reported a significant negative profit margin of -622.7%, highlighting substantial operational losses relative to its revenue base.
- With a market capitalization of $4.24M, the company operates at a very small scale, reflecting its early stage or limited market valuation.
- The company operates with a lean structure, employing only 2 individuals, which underscores its highly specialized and potentially outsourced operational model.
- Strategic expansion is underway with the announced intent to launch PoloMeds, a new service line targeting the diabetes and erectile dysfunction medication markets.
Who Are PMHS's Competitors?
PMHS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HEWA HealthWarehouse.com, Inc. | $0.11 | +0.00% | $6.29M | 55 |
| YI 111, Inc. | $3.44 | -1.99% | $30.1M | 44 |
| MYCOF Noveris Health Sciences Inc. | $0.73 | +0.00% | $42.7M | 48 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| HITI High Tide Inc. | $2.42 | -1.42% | $213M | 47 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.65 | +0.00% | $543M | 55 |
| CGEM Cullinan Therapeutics, Inc. | $22.52 | +8.06% | $1.38B | 57 |
| DMRA Galecto, Inc. | $30.31 | -6.57% | $1.87B | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PMHS's Key Strengths?
Specialization in compounding pharmacy services, offering customized medications not available commercially.
- Ownership of the SlimRx online platform, providing a direct-to-consumer channel for weight management solutions.
- Diverse product offerings including personalized dermatological compounds and planned expansion into diabetes and ED treatments.
- Integration into the growing telehealth market through prescription fulfillment for third-party platforms.
What Are PMHS's Weaknesses?
Very small operational scale with only 2 employees, potentially limiting capacity and resilience.
- Significant unprofitability, evidenced by a -622.7% profit margin, indicating substantial losses.
- Listing on the OTC Other tier, which typically implies lower transparency and higher investment risk.
- Low market capitalization of $4.24M, suggesting limited access to capital and market confidence.
What Could Drive PMHS Stock Higher?
PMHS catalyst: Successful launch and initial market penetration of the PoloMeds service, expanding the company's offerings into diabetes and erectile dysfunction treatments.
- Expansion of the SlimRx platform's marketing reach and patient acquisition efforts, leading to increased utilization of its weight management services.
- Growing demand for personalized compounded medications across various therapeutic areas, including dermatology and chronic disease management.
- Formation of new partnerships with additional third-party telehealth platforms, increasing the volume of prescription fulfillment services.
- Any improvements in financial performance, such as a reduction in the negative profit margin or an increase in market capitalization, signaling operational efficiencies.
What Are the Key Risks for PMHS?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant unprofitability, as evidenced by a -622.7% profit margin, posing a risk to long-term operational sustainability and requiring substantial capital infusion.
- High regulatory compliance risks inherent in compounding pharmacy operations, including potential for inspections, fines, or operational restrictions.
- Intense competition from larger, more established pharmaceutical companies, retail pharmacy chains, and well-funded telehealth providers.
- Operational challenges stemming from a very small employee base of 2, which could limit scalability, operational resilience, and ability to manage growth.
- Limited liquidity and high price volatility due to the company's listing on the OTC Other tier and its low market capitalization, making it difficult for investors to trade shares.
What Are the Growth Opportunities for PMHS?
- Growth opportunity 1: Expansion of the SlimRx Platform in Weight Management. The global weight loss and weight management market is projected to continue its robust growth, driven by rising obesity rates and increasing health consciousness. SlimRx, Polomar Health Services' online platform specializing in compounded semaglutide and other weight loss medications, is well-positioned to capitalize on this trend. By enhancing its marketing reach and potentially expanding its network of licensed medical professionals, SlimRx could significantly increase its patient base. The demand for effective, personalized weight loss solutions, particularly those involving GLP-1 agonists like semaglutide, offers a substantial market opportunity for scalable digital health platforms like SlimRx, with ongoing growth anticipated over the next 5-10 years.
- Growth opportunity 2: Launch and Development of the PoloMeds Service. Polomar Health Services' intent to launch PoloMeds, focusing on diabetes and erectile dysfunction (ED) medications, represents a strategic entry into two large and continuously growing therapeutic markets. The global diabetes drug market is substantial, driven by the increasing prevalence of diabetes worldwide, while the ED market also presents significant demand for effective treatments. By offering compounded metformin, sulfonylureas, insulin, and innovative treatments like inhalable sildenafil, PoloMeds can target patients seeking customized or alternative formulations. Successful execution of this launch, including regulatory compliance and market penetration, could unlock significant new revenue streams for the company within the next 1-3 years.
- Growth opportunity 3: Enhanced Focus on Personalized Dermatological Compounds. The market for dermatological treatments is vast, and there is a growing demand for personalized solutions for complex or chronic skin conditions. Polomar Health Services' existing capability to formulate customized compounds for conditions such as acne, alopecia areata, basal cell carcinoma, Becker's nevus, and vitiligo positions it uniquely. By expanding its range of dermatological offerings, collaborating with more dermatologists, and increasing awareness of its specialized services, the company can capture a larger share of this niche but high-value market. The ability to provide tailored medications offers a competitive advantage over mass-produced products, appealing to patients with specific needs over the long term.
- Growth opportunity 4: Deepening Integration with Third-Party Telehealth Platforms. The telehealth market has experienced exponential growth, with projections indicating continued expansion as healthcare delivery shifts towards virtual models. Polomar Health Services' role in supporting third-party web-based telehealth platforms by providing prescription fulfillment services places it directly within this growth trajectory. By forging new partnerships with additional telehealth providers and expanding the scope of its fulfillment services, the company can scale its operations without incurring the full costs of direct patient acquisition. This strategy leverages the broader telehealth ecosystem's growth, offering a scalable business model with opportunities for increased transaction volumes over the next 3-5 years.
- Growth opportunity 5: Capitalizing on the Niche Demand for Compounding Pharmacy Services. The core business of operating a retail compounding pharmacy addresses a fundamental need for customized medications that are not commercially available. This niche market is driven by patient allergies, specific dosage requirements, unique delivery methods, or discontinued medications. As healthcare becomes more patient-centric, the demand for personalized medicine is expected to rise. Polomar Health Services can strengthen its market position by investing in advanced compounding technologies, expanding its formulary, and enhancing its reputation for quality and safety. This specialization provides a defensible market segment with consistent demand from patients and prescribers seeking tailored pharmaceutical solutions.
What Are PMHS's Competitive Advantages?
- Specialization in compounding pharmacy, offering customized medications tailored to individual patient needs, which differentiates it from standard pharmacies.
- Ownership of proprietary online platforms like SlimRx, providing a direct-to-consumer channel for specific health services such as weight management.
- Expertise in formulating a diverse range of specialized compounds, including complex dermatological treatments and innovative delivery methods like inhalable sildenafil.
- Integration into the telehealth ecosystem by supporting third-party platforms, creating a network effect and recurring service revenue.
- Agility and responsiveness to niche market demands, allowing for rapid deployment of new specialized services like the planned PoloMeds.
What Does PMHS Do?
Polomar Health Services, Inc., headquartered in Los Angeles, California, operates as a specialized retail compounding pharmacy. The company's core business revolves around formulating customized medications tailored to individual patient needs, a practice distinct from mass-produced pharmaceuticals. A significant component of its operations is SlimRx, an owned online platform dedicated to weight management. Through SlimRx, Polomar Health Services connects patients with licensed medical professionals who can prescribe weight loss medications, frequently including compounded semaglutide, often enhanced with vitamin B-12 or metformin to optimize patient outcomes. This direct-to-consumer approach via a digital platform represents a modern strategy in healthcare delivery. Beyond weight management, Polomar Health Services is deeply involved in personalized dermatological compounds. The company formulates specialized treatments for a wide array of skin conditions, addressing concerns such as acne, alopecia areata, basal cell carcinoma, Becker's nevus, and vitiligo. This segment caters to patients requiring precise, custom-blended topical or oral medications that are not readily available in standard formulations. Furthermore, the company extends its services to support third-party web-based telehealth platforms by providing essential prescription fulfillment services, thereby integrating into the broader digital health ecosystem. Looking ahead, Polomar Health Services has announced its intention to launch PoloMeds, a new service line designed to target chronic conditions. PoloMeds is expected to focus on diabetes medications, including metformin compounds, sulfonylureas, and insulin, as well as compounded erectile dysfunction treatments, such as innovative inhalable sildenafil formulations. With a lean operational structure, managing 2 employees, Polomar Health Services positions itself in niche, high-demand areas of personalized medicine and digital health support.
What Products and Services Does PMHS Offer?
- Operates a retail compounding pharmacy specializing in customized medications for individual patient needs.
- Owns and manages SlimRx, an online platform connecting patients with medical professionals for weight management prescriptions.
- Provides compounded semaglutide, often mixed with vitamin B-12 or metformin, for weight loss treatments via SlimRx.
- Formulates personalized dermatological compounds to treat various skin conditions, including acne, alopecia areata, and vitiligo.
- Supports third-party web-based telehealth platforms by offering prescription fulfillment services.
- Intends to launch PoloMeds, a new service focused on diabetes medications such as metformin compounds, sulfonylureas, and insulin.
- Plans to offer compounded erectile dysfunction treatments, including innovative inhalable sildenafil formulations, through PoloMeds.
How Does PMHS Make Money?
- Generates revenue primarily from the sale of customized compounded medications directly to patients through its retail pharmacy and online platforms.
- Earns fees from services provided via its SlimRx online platform, facilitating patient access to licensed medical professionals for weight management prescriptions.
- Receives compensation for prescription fulfillment services provided to third-party web-based telehealth platforms.
- Anticipates future revenue streams from the planned PoloMeds service, offering specialized diabetes and erectile dysfunction treatments.
- Leverages its compounding expertise to create high-value, personalized pharmaceutical solutions not available through traditional pharmacies.
What Industry Does PMHS Operate In?
Polomar Health Services, Inc. operates within the dynamic healthcare sector, specifically carving a niche in the Medical - Pharmaceuticals industry through its focus on compounding pharmacy services and digital health platforms. The broader healthcare market is characterized by increasing demand for personalized medicine, a trend driven by individual patient needs and the limitations of standardized treatments. The rise of telehealth services, accelerated by technological advancements and shifting patient preferences, also represents a significant market trend that PMHS leverages through its support for third-party platforms. The competitive landscape for compounding pharmacies is fragmented, with numerous local and regional players, while the online weight management and specialized medication markets face competition from larger pharmaceutical companies and established telehealth providers. Polomar Health Services positions itself by combining specialized compounding expertise with direct-to-consumer digital channels like SlimRx and the upcoming PoloMeds, aiming to capture market share in specific therapeutic areas where customized solutions are highly valued.
Who Are PMHS's Key Customers?
- Individuals seeking customized medication formulations due to specific health needs, allergies, or dosage requirements.
- Patients utilizing the SlimRx online platform for physician consultations and prescriptions related to weight management.
- Patients requiring specialized dermatological compounds for conditions like acne, alopecia areata, basal cell carcinoma, Becker's nevus, and vitiligo.
- Third-party web-based telehealth platforms that require reliable prescription fulfillment services for their patient base.
- Future customers seeking personalized diabetes medications and erectile dysfunction treatments through the upcoming PoloMeds service.
Company Profile
Polomar Health Services, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Terrence Tierney. PMHS has traded publicly since 2009.
How Polomar Health Services, Inc. Is Valued
Polomar Health Services, Inc. carries a market capitalization of $4.24M, placing it in the micro-cap category.
Key Financial Metrics
Its free cash flow yield is -7.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Polomar Health Services, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
The most recent 3 insider filings for Polomar Health Services, Inc. break down as 0 sales and 3 purchases. On net that is roughly 141K shares acquired (about $5.5B) — insiders putting money in tends to read as conviction.
PMHS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests strong confidence in the company's future performance.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative healthcare solutions.
- Polomar's recent partnerships with key healthcare providers have increased market visibility and credibility.
- Positive feedback from recent service expansions indicates a growing demand for their offerings.
Bear Case
- Concerns about regulatory challenges in the healthcare sector have emerged, potentially impacting future growth.
- Social sentiment has seen some skepticism regarding the company's ability to scale operations effectively.
- Recent negative press surrounding healthcare service quality could tarnish the company's reputation.
- Market perception remains cautious, with investors wary of potential economic headwinds affecting the healthcare industry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PMHS Latest News
No recent news available for PMHS.
PMHS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PMHS.
Price Targets
Wall Street price target analysis for PMHS.
PMHS MoonshotScore
What does this score mean?
The MoonshotScore rates PMHS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Terrence Tierney
CEO
Terrence Tierney's professional background prior to leading Polomar Health Services, Inc. is unknown from the provided information. His educational qualifications and previous career history, including roles at other organizations or specific industry experience before joining Polomar Health Services, are not detailed in the available data. As the individual managing the company's operations with a team of 2 employees, his role likely encompasses a broad range of responsibilities typical of a leader in a small, specialized healthcare enterprise.
Track Record: Specific achievements or strategic decisions made by Terrence Tierney during his tenure at Polomar Health Services, Inc. are not explicitly detailed in the provided source data. His leadership is associated with the current operational focus on customized compounding, the development of the SlimRx online platform for weight management, and the announced intent to launch the PoloMeds service for diabetes and erectile dysfunction treatments. The company's current financial metrics, including its gross margin of 61.1% and profit margin of -622.7%, reflect the operational and financial performance under his management.
PMHS OTC Market Information
Polomar Health Services, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group's three marketplaces. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which have stringent listing requirements regarding financial standards, corporate governance, and public disclosure, companies on the OTC Other tier face minimal disclosure obligations. This tier is typically for companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide information to the public. Investors should understand that this tier offers significantly less transparency and regulatory oversight compared to major exchanges, impacting the availability of reliable company information and investor protection.
- OTC Tier: OTC Other
- Lack of transparent and regular financial reporting, making it difficult to assess the company's true financial health and operational performance.
- Extremely low trading volume and wide bid-ask spreads, leading to significant illiquidity and potential difficulty in executing trades.
- High price volatility due to limited market depth and susceptibility to speculative trading or news events.
- Limited or no analyst coverage, resulting in a lack of independent research and valuation insights for investors.
- Increased risk of fraud or manipulation due to minimal regulatory oversight and disclosure requirements compared to major exchanges.
- Verify any available financial statements directly from the company or regulatory filings, scrutinizing revenue, expenses, and cash flow.
- Research the background and track record of CEO Terrence Tierney and other key personnel, if information becomes available.
- Thoroughly investigate the company's business operations, including its compounding processes, regulatory compliance, and market position in its niches.
- Assess the legitimacy and operational status of its online platforms, SlimRx, and the progress of the planned PoloMeds launch.
- Examine any public news, press releases, or legal documents related to the company's regulatory standing or potential litigation.
- Understand the specific market trends and competitive landscape within the compounding pharmacy and telehealth sectors.
- Evaluate the company's capital structure and any potential need for future financing, which could dilute existing shareholders.
- Operation of an existing online platform, SlimRx, for weight management, indicating active business operations.
- Specific and detailed plans for future service launches, such as PoloMeds for diabetes and ED treatments.
- Clear articulation of specialized product offerings, including compounded semaglutide and personalized dermatological compounds.
- Stated support for third-party web-based telehealth platforms, suggesting integration into a broader industry ecosystem.
- Headquarters in Los Angeles, California, providing a verifiable physical location for the company's operations.
Common Questions About PMHS (Healthcare)
What specific healthcare services does Polomar Health Services, Inc. provide?
Polomar Health Services, Inc. specializes in operating a retail compounding pharmacy, offering customized medications tailored to individual patient needs. A core service is its SlimRx online platform, which connects patients with licensed medical professionals for weight management, often prescribing compounded semaglutide, potentially combined with vitamin B-12 or metformin.
How does Polomar Health Services, Inc. generate revenue within the healthcare sector?
Polomar Health Services, Inc. generates revenue primarily through several distinct channels within the healthcare sector. A significant portion comes from the direct sale of its customized compounded medications, which are formulated to meet specific patient requirements not addressed by mass-produced drugs. This includes revenue from its specialized dermatological compounds and the compounded weight loss medications offered via its SlimRx platform.
What are the primary risks associated with investing in Polomar Health Services, Inc., particularly as an OTC-listed company?
Investing in Polomar Health Services, Inc. carries several notable risks, amplified by its listing on the OTC Other tier. A primary concern is the company's significant unprofitability, reflected in a -622.7% profit margin, indicating substantial ongoing losses. The compounding pharmacy sector is also subject to stringent and evolving regulatory oversight, posing compliance risks that could impact operations and financial performance.
What are the key growth opportunities for PMHS in the personalized medicine and telehealth markets?
Polomar Health Services, Inc. is strategically positioned to capitalize on several growth opportunities within the personalized medicine and telehealth markets. The increasing demand for customized medications, driven by individual patient needs and preferences, provides a strong foundation for its compounding pharmacy services.
What are the key factors to evaluate for PMHS?
Evaluate PMHS on fundamentals, analyst consensus, and risk factors. Polomar Health Services, Inc. presents an investment thesis centered on its specialization in compounding pharmacy services and strategic expansion into high-demand therapeutic areas. Not financial advice.
How frequently does PMHS data refresh on this page?
PMHS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PMHS's recent stock price performance?
Polomar Health Services, Inc. (PMHS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in compounding pharmacy services, offering customized medications not available commercially. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PMHS overvalued or undervalued right now?
Polomar Health Services, Inc. (PMHS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Lack of historical financial data beyond specified metrics, CEO background, and specific market share data limits comprehensive analysis.
- Competitor information (FMP PEER TICKERS) was not provided in the source data, hence the empty array for competitors.
- The market capitalization of $4.24M is used as stated in 'FINANCIALS', despite an AI insight mentioning $2.02M, to adhere strictly to provided 'FINANCIALS' data.
- CEO title assumed as 'CEO' given the context of managing employees for a company.